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Background: Amrubicin is a synthetic anthracycline drug that is a
potent inhibitor of topoisomerase II. We have performed a multicenter
phase II trial to evaluate the efficacy and safety of amrubicin for patients
with previously treated non-small cell lung cancer (NSCLC).
Methods: Patients with advanced NSCLC who experienced disease
recurrence after one platinum-based chemotherapy regimen were eligi-
ble for enrollment in the study. Amrubicin was administered by intra-
venous injection at a dose of 40 mg/m2 on 3 consecutive days every 3
weeks.
Results: Sixty-one enrolled patients received a total of 192 treat-
ment cycles (median, 2; range, 1–15). Response was as follows:
complete response, 0; partial response, seven (11.5%); stable dis-
ease, 20 (32.8%); and progressive disease, 34 (55.7%). Median
progression-free survival was 1.8 months, whereas median overall
survival was 8.5 months, and the 1-year survival rate was 32%.
Hematologic toxicities of grade 3 or 4 included neutropenia
(82.0%), leukopenia (73.8%), thrombocytopenia (24.6%), and ane-
mia (27.9%). Febrile neutropenia occurred in 18 patients (29.5%).
One treatment-related death due to infection was observed. Nonhe-
matologic toxicities were mild.
Conclusions: Amrubicin is a possible alternative for second-line
treatment of advanced NSCLC, although a relevant hematological
toxicity is significant, especially with a febrile neutropenia.
Key Words: Amrubicin, Non-small cell lung cancer (NSCLC),
Platinum refractory, Second-line chemotherapy.
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Non-small cell lung cancer (NSCLC) is the leading causeof death related to cancer worldwide.1 The first-line
platinum-based chemotherapy confers a moderate improve-
ment in survival and quality of life in individuals with
advanced NSCLC.2,3 It has recently become generally ac-
cepted that the second-line chemotherapy also has beneficial
effects on survival and quality of life in such patients.3–5
Despite the availability of several options for the second-line
treatment of NSCLC,6 however, the life expectancy of pa-
tients with advanced disease remains short, highlighting the
urgent need for new treatments.
Amrubicin is a fully synthetic anthracycline anticancer
drug with a similar structure to doxorubicin and is a potent
inhibitor of topoisomerase II.7–9 Two phase II trials of am-
rubicin administered as a single agent yielded response rates
of 18.7 to 27.9% with acceptable toxicities in chemotherapy-
naive patients with advanced NSCLC,10,11 suggestive of
promising activity for such patients. However, the activity
and safety of amrubicin for patients with NSCLC whose
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disease progresses after first-line chemotherapy have not been
previously described.
Therefore, we conducted a multicenter phase II trial of
amrubicin in patients with NSCLC previously treated with
platinum-based chemotherapy. This trial was designed to
determine the antitumor activity and toxicity of amrubicin in
the second-line setting.
PATIENTS AND METHODS
Patient Selection
The eligibility criteria for participation of subjects in
the trial included histologic or cytologic evidence of NSCLC;
stage IV or stage IIIB disease (including only patients with no
indications for curative thoracic radiotherapy) at study entry;
recurrent or refractory disease after one previous platinum-
containing chemotherapy regimen; measurable disease; no
chemotherapy or radiotherapy within the 4 weeks before
study entry; an age of 20 to 74 years; an Eastern Cooperative
Oncology Group performance status of 0 or 1; adequate bone
marrow function (leukocyte count of 4000 and 12,000/
mm3, neutrophil count of 2000/mm3, platelet count of
100,000/mm3, and hemoglobin content of 9.5 g/dl); ad-
equate other organ function (serum total bilirubin concentra-
tion of 1.5 mg/dl, serum aspartate aminotransferase and
alanine aminotransferase levels of 2.5 times the upper
normal limit, and normal serum creatinine concentration);
partial pressure of arterial oxygen of 60 torr; no abnormal-
ity on the electrocardiogram requiring treatment; and a left
ventricular ejection fraction of 60% on echocardiography.
Patients were ineligible for participation in the study if they
had undergone previous amrubicin therapy, a history of a
cumulative doxorubicin dose 500 mg/m2 (epirubicin 900
mg/m2, pirarubicin 950 mg/m2, and daunorubicin 25
mg/kg), symptomatic brain metastasis, third-space fluid col-
lection requiring drainage, active concomitant malignancy,
radiographic signs of interstitial pneumonia or pulmonary
fibrosis, a serious or uncontrolled concomitant systemic dis-
order (active infection, active gastric or duodenal ulcer, heart
disease, diabetes mellitus, or a condition requiring chronic
systemic administration of corticosteroids), or a history of
drug allergy, or if they were lactating or pregnant. This study
was performed in accordance with the principles of the
Declaration of Helsinki and the good clinical practice guide-
lines. Written informed consent was obtained from all pa-
tients before study entry. Trial document approval was ob-
tained from the institutional review board of each
participating institution.
Study Design and Sample Size
The study was a multicenter, open-label, single-arm,
phase II study. The primary end point was the response rate
for amrubicin in patients with recurrent or refractory NSCLC
who experienced treatment failure with platinum-based che-
motherapy, which determined the sample size based on an
optimal two-stage design.12 On the basis of the results of
previous studies, the proposed regimen was to be considered
worthy or not worthy for additional investigation in the
selected patient population if a true response rate was ob-
tained of 18 or 5%, respectively, with a power of 0.9 and
an  error of 0.05. A total of 55 assessable patients was
necessary for the study; 23 in the first stage and 32 in the
second stage. Assuming a drop-out rate of 10%, we planned
on enrolling 60 patients in the study.
Treatment
Amrubicin was reconstituted in 20 ml of physiological
saline or 5% glucose solution and was administered intrave-
nously for more than 5 minutes at a dose of 40 mg/m2 per day
on days 1 to 3 every 3 weeks. Patients with evidence of
disease progression or who experienced unacceptable adverse
events were withdrawn from the study. Other criteria for
treatment discontinuation included treatment refusal by the
patient, inadvertent enrollment in the study, use of excluded
concomitant therapy, or a decision by the physician to stop
treatment. Subsequent courses of treatment were withheld
until the following criteria were satisfied: the leukocyte count
was 3000/mm3, the neutrophil count was 1500/mm3, the
platelet count was 100,000/mm3, and the grade of any
nonhematologic toxicity was 2. If these criteria were not
satisfied within 43 days after the onset of the last treatment,
the patient was removed from the study. The dose of amru-
bicin was reduced to 35 mg/m2 per day if leukopenia or
neutropenia of grade 4 for more than 4 days, febrile neutro-
penia, thrombocytopenia of grade 4, or nonhematologic tox-
icity of grade 3 (or of grade 4 for anorexia, nausea, body
weight loss, or hyponatremia) occurred during the previous
course. If these toxicities occurred after reduction of the
amrubicin dose to 35 mg/m2 per day, the dose was reduced
further to 30 mg/m2 per day. The third reduction of amrubicin
dose was not allowed.
Evaluation
Tumor response was assessed according to the Re-
sponse Evaluation Criteria in Solid Tumors.13 Tumors were
measured by computed tomography within 4 weeks before
the first cycle of treatment. The same measurement was
performed every 4 weeks from the onset of treatment. A
central radiologic review was performed to determine the
eligibility of patients and the response to treatment. Response
was confirmed at least 4 (for a complete or partial response)
or 6 weeks (for stable disease) after it was first documented.
Progression-free survival was defined as the time from reg-
istration until objective tumor progression or death. Patients
whose disease had not progressed at the time of discontinu-
ation of the study treatment were assessed until progression
was documented. If a patient died without documentation of
disease progression, the patient was considered to have had
tumor progression at the time of death, unless there was
sufficient documented evidence to conclude otherwise. Over-
all survival was defined as the time from registration until
death from any cause. Progression-free and overall survival
and the 1-year survival rate were estimated by the Kaplan-
Meier method. Adverse events were graded according to
National Cancer Institute Common Toxicity Criteria (version
3). All patients who received one dose of chemotherapy were
assessable for toxicity. Clinical and laboratory assessment
was performed at least once a week.
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RESULTS
Patient Characteristics
Between February 2005 and March 2006, 61 patients
were enrolled in the study at 12 participating institutions. All
patients were eligible for the study and assessable both for the
efficacy and safety of treatment and for survival. The char-
acteristics of the study subjects are summarized in Table 1.
Thirty-nine patients were men and 22 were women, and their
median age was 63 years, with a range of 51 to 74 years.
Histologic analysis revealed that 40 patients (65.6%) had
adenocarcinoma, and 14 patients (23.0%) had squamous
cell carcinoma. Forty-eight patients (78.7%) had stage IV
disease, and the other 13 patients had stage IIIB disease at
the time of enrollment in the study. All 61 patients had
been previously treated with platinum-based chemother-
apy, with eight and 22 patients having also undergone
surgery or radiation therapy, respectively, before enroll-
ment in the study.
Treatment Administered
Patients received a median of two cycles of treatment
(range, 1–15), with 16 patients (26.2%) receiving at least
four cycles. A total of 192 cycles of treatment was deliv-
ered overall. The mean relative dose intensity of amrubicin
was 87.3%. Dose reduction of amrubicin was necessary
according to the study protocol in 22 cycles (11.5% of total
cycles). The major reasons for dose reduction were neu-
tropenia or leukopenia of grade 4 (13 cycles of all cycles)
and febrile neutropenia (nine cycles of all cycles). Treat-
ment was discontinued in 14 patients after the first cycle
and in 17 patients after the second cycle; the reasons for
discontinuation included progressive disease (25 patients),
toxicity (four patients), and patient refusal (two patients).
Poststudy, 71% of patients eventually received subsequent
therapies. Twenty-eight patients (46%) received do-
cetaxel-containing chemotherapy, 18 (26%) received ge-
fitinib or erlotinib, and 30 (49%) received other chemo-
therapy.
Response and Survival
Among the 61 assessable patients, there were seven
partial responses and no complete responses, for an overall
response rate of 11.5% (95% confidence interval [CI], 4.7–
22.2) (Table 2). Twenty patients (32.8%) had stable disease,
yielding an overall disease control rate (complete response 
partial response  stable disease) of 44.3% (95% CI, 31.5–
57.6). Thirty-four patients had progressive disease as the
best response. No correlation was apparent between the
response rate and sex, age, tumor histology, disease stage,
or smoking status.
Of the 61 subjects, 11 patients were still alive as of
October 2008. The progression-free survival curve is shown
in Figure 1; the median progression-free survival was 1.8
months (95% CI, 1.4–2.3). The curve for overall survival is
shown in Figure 2; the median overall survival time was 8.5
months (95% CI, 7.7–10.4), and the 1-year survival rate was
32% (95% CI, 20.7–44.0).
Safety
The adverse events observed for all 61 treated patients
are summarized in Table 3. The most frequent toxicity was
myelosuppression, which mostly affected leukocytes. Neu-
tropenia or leukopenia of grade 3 occurred in 82.0% and
73.8% of patients, respectively. Anemia and thrombocytope-
nia of grade 3 were relatively infrequent, occurring in
27.9% and 24.6% of patients, respectively. Eighteen patients
(29.5%) developed febrile neutropenia. The most common
TABLE 1. Characteristics of the 61 Eligible Patients
Characteristic No. of Patients (%)
Median age (yr)
70 48 (78.7)
70 13 (21.3)
Sex
Male 39 (63.9)
Female 22 (36.1)
Performance status (ECOG)
0 15 (24.6)
1 46 (75.4)
Disease stage
III B 13 (21.3)
IV 48 (78.7)
Tumor histology
Adenocarcinoma 40 (65.6%)
Squamous cell carcinoma 14 (23.0%)
Large cell carcinoma 3 (4.9)
NSCLC, not specified 4 (6.6)
Prior therapy
Chemotherapy 61 (100)
Radiotherapy 22 (36.1)
Surgery 8 (13.1)
Time since last chemotherapy
3 mo 28 (46.0)
3–6 mo 16 (26.0)
6 mo 17 (28.0)
Response to prior chemotherapy
Complete response 1 (1.6)
Partial response 36 (59.0)
Stable or progressive disease 19 (31.1)
Not evaluable 5 (8.2)
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
TABLE 2. Overall Response Rate for Amrubicin (Response
Evaluation Criteria in Solid Tumors) as Determined by
Independent Radiological Assessment
Response No. of Patients
Complete response 0
Partial response 7 (11.5%; 95% CI, 4.7–22.2)
Overall response 7 (11.5%)
Stable disease 20 (32.8%)
Disease control 27 (44.3%; 95% CI, 31.5–57.6)
Progressive disease 34 (55.7%)
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nonhematologic toxicities of grade 3 or 4 were anorexia
(9.8%), asthenia (6.6%), an increase in serum alanine ami-
notransferase and aspartate aminotransferase levels (6.6%),
and infection (6.6%), but most nonhematologic toxicities
were mild. No cardiac toxicity was observed during the study.
Pneumonitis of grade 3 occurred in one patient. One treat-
ment-related death due to sepsis after febrile neutropenia
occurred.
DISCUSSION
Amrubicin is a novel, fully synthetic anthracycline
agent that is active against both NSCLC and small cell lung
cancer (SCLC).10,11,14–16 No prospective study evaluating the
efficacy and safety of amrubicin for previously treated
NSCLC has been reported. We have now demonstrated the
efficacy of amrubicin monotherapy for patients with NSCLC
previously treated with platinum-based chemotherapy, as
shown by a response rate of 11.5%, median overall survival
of 8.5 months, and 1-year survival rate of 32% in 61 patients.
Previous phase III trials for second- or third-line treatment of
NSCLC have shown response rates of 7.6 to 9.1%, median
overall survival times of 6.7 to 8.3 months, and 1-year
survival rates of 29.7 to 34%.4,5,17–19 Amrubicin is a potent
inhibitor of topoisomerase II, with its mechanism of action
differing from those of currently available active agents for
advanced NSCLC.7–9 Given the encouraging results from our
trial and the unique mode of action of amrubicin, this drug is
a good candidate for the development of a new second-line
treatment for NSCLC.
Treatment was discontinued in 14 patients after the first
cycle and 17 patients after the second cycle. Of these 31
patients, 25 patients were withdrawn because of progressive
disease. The study protocol required assessment of antitumor
effect by computed tomography every 4 weeks. Such assess-
ment, performed to avoid ineffective therapy, resulted in
early discontinuation of treatment due to progressive disease
and thereby yielded a median progression-free survival that
was slightly shorter than otherwise might have been obtained.
Two recent phase II trials of amrubicin for previously
treated SCLC, in which the drug was administered at the
FIGURE 1. Kaplan-Meier analysis of progression-
free survival for all 61 treated patients.
FIGURE 2. Kaplan-Meier analysis of overall sur-
vival for all 61 treated patients.
TABLE 3. Toxicity for all 61 Patients During Amrubicin
Monotherapy According to the National Cancer Institute
Common Toxicity Criteria (Version 3)
Toxicity
Grade Grade >3
1 2 3 4 No. Percentage
Leukopenia 5 8 24 21 45 73.8
Neutropenia 0 5 8 42 50 82.0
Anemia 16 27 13 4 17 27.9
Thrombocytopenia 25 7 7 8 15 24.6
Febrile neutropenia 0 0 18 0 18 29.5
Anorexia 19 9 5 1 6 9.8
Nausea 20 5 2 0 2 3.3
Vomiting 7 3 0 0 0 0
Asthenia 18 13 2 2 4 6.6
Infection 0 1 2 1 4a 6.6
Fever 10 6 1 0 1 1.6
Elevation of AST or ALT 15 3 1 3 4 6.6
Pneumonitis 1 0 1 0 1 1.6
a Includes one treatment-related death (grade 5).
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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same dose and according to the same schedule as in the
present study, found that treatment was associated with a high
incidence of bone marrow suppression, although drug toxic-
ity was manageable.20,21 Consistent with these results, the
major adverse events in this study were hematologic toxici-
ties of grade 3 or 4 including neutropenia (82.0%), leukope-
nia (73.8%), anemia (27.9%), and thrombocytopenia
(24.6%). The incidence of these toxicities in this study was
similar to that observed previously in the phase II trials for
previously treated SCLC. However, the incidence of febrile
neutropenia of grade 3 was higher in our study (29.5%) than
in these previous trials (5–14%). One possible explanation for
this difference is the frequent use of granulocyte colony-
stimulating factor for treatment of SCLC, when compared
with treatment for NSCLC. The incidents of significant neu-
tropenia and febrile neutropenia were seen primarily in the
first cycle. In this study, patients who experienced severe
hematologic toxicities were not allowed to receive prophy-
lactically granulocyte colony-stimulating factor in subsequent
cycles. One treatment-related death due to sepsis after febrile
neutropenia occurred in our study. Therefore, it is important
to monitor closely leukocyte and neutrophil counts during
amrubicin therapy in patients with previously treated
NSCLC. Nonhematologic toxicity was manageable in this
study. Another adverse event of particular concern for amru-
bicin is cardiac toxicity, given that the chemical structure of
the drug is similar to that of doxorubicin, whose cardiac
toxicity has been experimentally and clinically established.
Indeed, cardiac toxicity was detected in previous trials of
amrubicin, although its frequency (3.2%) was relatively
low.10,11 For safety reasons, this study allowed the enrollment
only of patients with a left ventricular ejection fraction of
60% as determined by echocardiography. No cardiac tox-
icity was observed during our trial, even in the three patients
who received more than eight cycles of amrubicin therapy.
In conclusion, in this first reported phase II study of the
efficacy and safety of amrubicin monotherapy as a second-
line treatment for advanced NSCLC previously treated with
platinum-based chemotherapy, we obtained a response rate,
overall survival, and 1-year survival rate comparable with
those of other second-line treatment regimens. This activity
despite a relevant hematological toxicity of amrubicin mono-
therapy is a possible alternative for second-line treatment of
advanced NSCLC. Further evaluation of amrubicin for re-
fractory or relapsed NSCLC in randomized phase III trials is
warranted.
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